The dynamics of tumour-vasculature interaction suggests low-dose, time-dense anti-angiogenic schedulings

Cell Proliferation

Volumn 42, Issue 3, 2009, Pages 317-329

  D'Onofrio, A ^a   Gandolfi, A ^a,b   Rocca, A ^a,c  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b CNR   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR;

ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; COMPARATIVE STUDY; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG INFUSION; LOW DRUG DOSE; MATHEMATICAL MODEL; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MODELS, THEORETICAL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 65349170905     PISSN: 09607722     EISSN: 13652184     Source Type: Journal    
DOI: 10.1111/j.1365-2184.2009.00595.x     Document Type: Article

References (62)

1. Folkman J (1985) Tumour angiogenesis. Adv. Cancer Res. 43, 175 203.
2. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407, 249 257.
3. Folkman J (2007) Opinion - angiogenesis: an organizing principle for drug discovery? Nat. Rev. Drug Disc. 6, 273 286. (Pubitemid 46505878)
4. Yu JL, Rak JW (2003) Host microenvironment in breast cancer development: Inflammatory and immune cells in tumour angiogenesis and arteriogenesis. Breast Cancer Res. 5, 83 88.
5. Kim KJ, Li B, Winer J, Armanini M, Gillet N, Phillips HS et al 1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362, 841 844. (Pubitemid 23132159)
6. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS et al 1997) Endostatin: an endogenous inhibitor of angiogenesis and tumour growth. Cell 88, 277 285. (Pubitemid 28015876)
7. O'Reilly MS, Holmgren L, Chen C, Folkman J (1996) Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med. 2, 689 692. (Pubitemid 26191958)
8. Boehm T, Folkman J, Browder T, O'Reilly MS (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390, 404 407. (Pubitemid 28027321)
9. Kerbel RS, Yu J, Tran J, Man S, Viloria-Petit A, Klement G et al 2001) Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis. Rev. 20, 79 86. (Pubitemid 34074682)
10. Kerbel R, Folkman J (2002) Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer 2, 727 739. (Pubitemid 37328908)
11. Anderson ARA, Chaplain MA (1998) Continuous and discrete mathematical models of tumor-induced angiogenesis. Bull. Math. Biol. 60, 857 899. (Pubitemid 28427465)
12. Hahnfeldt P, Panigrahy D, Folkman J, Hlatky L (1999) Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res. 59, 4770 4775. (Pubitemid 29472873)
13. De Angelis E, Preziosi L (2000) Advection-diffusion models for solid tumour evolution in vivo and related free boundary problem. Math. Models Methods Appl. Sci. 10, 379 408.
14. Alarcon T, Byrne HM, Maini PK (2003) A cellular automaton model for tumour growth in inhomogeneous environment. J. Theor. Biol. 225, 257 274. (Pubitemid 37324088)
15. Agur Z, Arakelyan L, Daugulis P, Ginosar Y (2004) Hopf point analysis for angiogenesis models. Discrete Continuous Dynam Syst. B 4, 29 38. (Pubitemid 38202953)
16. d'Onofrio A, Gandolfi A (2004) Tumour eradication by antiangiogenic therapy: analysis and extensions of the model by Hahnfeldt et al. (1999). Math. Biosci. 191, 159 184. (Pubitemid 39195231)
17. Forys U, Kheifetz Y, Kogan Y (2005) Critical-point analysis for three-variable cancer angiogenesis models. Math. Biosc. Eng. 2, 511 525.
18. McDougall SR, Anderson ARA, Chaplain MAJ (2006) Mathematical modelling of dynamic adaptive tumour-induced angiogenesis: Clinical implications and therapeutic targeting strategies. J. Theor. Biol. 241, 564 589. (Pubitemid 44041121)
19. Stamper IJ, Byrne HM, Owen MR, Maini PK (2007) Modelling the role of angiogenesis and vasculogenesis in solid tumuour growth. Bull. Math. Biol. 69, 2737 2772. (Pubitemid 350029426)
20. d'Onofrio A, Gandolfi A (2009) A family of models of angiogenesis and antiangiogenic anticancer therapy. Math. Med. Biol. 26, 63 95.
21. Ledzewicz U, Schättler H (2007) Anti-angiogenic therapy in cancer treatment as an optimal control problem. SIAM J. Control. Optimization 46, 1053 1079.
22. Tee D, Distefano J III (2004) Simulation of tumor-induced angiogenesis and its response to antiangiogenic drug treatment: mode of drug delivery and clearance rate dependencies. J. Cancer Res. Clin. Oncol. 130, 15 24. (Pubitemid 38161243)
23. Wheldon TE (1988) Mathematical Models in Cancer Research. Boston : Hilger Publishing.
24. Sachs RK, Hlatky LR, Hahnfeldt P (2001) Simple ODE models of tumour growth and anti-angiogenic or radiation treatment. Math. Comput. Modelling 33, 1297 1305. (Pubitemid 32417939)
25. Bodnar M, Forys U (2007) Three types of simple DDE's describing tumour growth. J. Biol. Sys. 15, 453 471. (Pubitemid 350261761)
26. d'Onofrio A (2005) A general framework for modelling tumour-immune system and immunotherapy: mathematical analysis and medical inferences. Physica D 208, 220 235.
27. Gibaldi M, Perrier D (1982) Pharmacokinetics. New York : Marcel Dekker.
28. Bertuzzi A, Fasano A, Filidoro L, Gandolfi A, Sinisgalli C (2005) Dynamics of tumour cords following changes of oxygen availability: a model including a delayed exit from quiescence. Math. Comput. Modelling 41, 1119 1135. (Pubitemid 41444868)
29. Shackney SE, Shankey TV (1999) Cell cycle models for molecular biology and molecular oncology: exploring new dimensions. Cytometry 35, 97 116. (Pubitemid 29053246)
30. d'Onofrio A (2008) Fractal growth of tumors and other cellular populations: linking the mechanistic to the phenomenological modelling and vice versa. Chaos Solitons Fractals DOI:.
31. Hahnfeldt P, Folkman J, Hlatky L (2003) Minimizing long-term tumour burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic bias. J. Theor. Biol. 220, 545 554. (Pubitemid 36293163)
32. Morishita T, Mii Y, Miyauchi Y, Miura S, Honoki K, Aoki M et al 1995) Efficacy of the angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (AGM-1470) on osteosarcoma growth and lung metastasis in rats. Jpn. J. Clin. Oncol. 25, 25 31.
33. Drixler TA, Borel Rinkes IHM, Ritchie ED, van Vroonhoven TJMV, Gebbink MFBG, Voest EE (2000) Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy. Cancer Res. 60, 1761 1765. (Pubitemid 30183453)
34. Kisker O, Becker CM, Prox D, Fannon M, D'Amato R, Flynn E et al 2001) Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res. 61, 7669 7674. (Pubitemid 32995064)
35. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS et al 2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60, 1878 1886. (Pubitemid 30207647)
36. Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci. G, Nole F et al 2002) Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann. Oncol. 13, 73 80. (Pubitemid 34436728)
37. Herbst RS, Hess KR, Tran HT, Tseng JE, Mullani NA, Charnsangavej C et al 2002) Phase I study of recombinant human endostatin in patients with advanced solid tumors. J. Clin. Oncol. 20, 3792 3803.
38. Eder JP Jr., Supko JG, Clark JW, Puchalski TA, Garcia-Carbonero R, Ryan DP et al 2002) Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J. Clin. Oncol. 20, 3772 3778.
39. Thomas JP, Arzoomanian RZ, Alberti D, Alberti D, Marnocha R, Lee F et al 2003) Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J. Clin. Oncol. 21, 223 231. (Pubitemid 46606150)
40. Hansma AH, Broxterman HJ, van der Horst I, Yuana Y, Boven E, Giaccone G et al 2005) Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer. Ann. Oncol. 16, 1695 1701. (Pubitemid 41510146)
41. Kulke MH, Bergsland EK, Ryan DP, Enzinger PC, Lynch TJ, Zhu AX et al 2006) Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J. Clin. Oncol. 24, 3555 3561. (Pubitemid 46630526)
42. DeMoraes ED, Fogler WE, Grant D, Wahl N, Leeper D, Zrada S et al 2001) Recombinant human angiostatin (rhA): a Phase I clinical trial assessing safety, pharmacokinetics (PK) and pharmacodynamics (PD). Proc. Am. Soc. Clin. Oncol. 20, abstract no. 10.
43. Beerepoot LV, Witteveen EO, Groenewegen G, Fogler WE, Sim BKL, Sidor C et al 2003) Recombinant human angiostatin by twice-daily subcutaneous injection in advanced cancer: a pharmacokinetic and long-term safety study. Clin. Cancer Res. 9, 4025 4033. (Pubitemid 37204017)
44. Kurup A, Lin CW, Murry DJ, Dobrolecki L, Estes D, Yiannoutsos CT et al 2006) Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer: a phase II study from Indiana University. Ann. Oncol. 17, 97 103. (Pubitemid 43033847)
45. Bhargava P, Marshall JL, Rizvi N, Dahut W, Yoe J, Figuera M et al 1999) A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. Clin. Cancer Res. 5, 1989 1995. (Pubitemid 29399248)
46. Herbst RS, Madden TL, Tran HT, Blumenschein GR, Meyers CA, Seabrooke LF et al 2002b) Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. J. Clin. Oncol. 20, 4440 4447. (Pubitemid 35334755)
47. Gordon MS, Margolin K, Talpaz M, Sledge GW, Holmgren E, Benjamin R et al 2001) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. 19, 843 850. (Pubitemid 32119100)
48. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al 2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335 2342. (Pubitemid 38702844)
49. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A et al 2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355, 2542 2550.
50. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA et al 2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357, 2666 2676.
51. Jain RK, Duda DG, Clark JW, Loeffler JS (2006) Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 3, 24 40. (Pubitemid 43108832)
52. Stopeck A, Sheldon M, Vahedian M, Cropp G, Gosalia R, Hannah A (2002) Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Clin. Cancer Res. 8, 2798 2805.
53. Kuenen BC, Tabernero J, Baselga J, Cavalli F, Pfanner E, Conte PF et al 2003) Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin. Cancer Res. 9, 1648 1655. (Pubitemid 36554587)
54. Fury MG, Zahalsky A, Wong R, Venkatraman E, Lis E, Hann L et al 2007) A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers. Invest. New Drugs 25, 165 172. (Pubitemid 46020876)
55. Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A et al 2003) Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J. Clin. Oncol. 21, 3955 3964.
56. Thomas AL, Morgan B, Horsfield MA, Higginson A, Kay A, Lee L et al 2005) Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J. Clin. Oncol. 23, 4162 4171.
57. Hecht JR, Trarbach T, Jaeger E, Hainsworth J, Wolff R, Lloyd K et al 2005) A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). J. Clin. Oncol. (2005 ASCO Annual Meeting Proceedings) 23 (16S, Suppl LBA3.
58. Kohne C, Bajetta E, Lin E, Valle JW, Van Cutsem E, Hecht JR et al 2007) Final results of CONFIRM 2: a multinational, randomized, double-blind, phase III study in 2nd line patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo. J. Clin. Oncol. (2005 ASCO Annual Meeting Proceedings) 25 (18S, Suppl 4033.
59. Rosen L, Mulay M, Long J, Wittner J, Brown J, Martino AM et al 2003) Phase I trial of SU011248, a novel tyrosine kinase inhibitor in advanced solid tumours. Proc. Am. Soc. Clin. Oncol. 22, Abstract 765.
60. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M et al 2005) Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J. Clin. Oncol. 23, 965 972. (Pubitemid 46202316)
61. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O et al 2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115 124. (Pubitemid 46089672)
62. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M et al 2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125 134. (Pubitemid 46089673)